Healthcare technology company Lifespot Health has appointed two cannabinoid specialists as non-executive board directors to help execute its strategy of delivering medication systems and therapies to market.
Dr Andrew Saich was European medical director for Intercept Pharmaceuticals when the company was expanding into 13 countries across Europe and, in 2016, he created and led GW Pharmaceuticals International Medical in preparation for the launch of Epidyolex for the treatment of rare and debilitating drug-resistant epilepsies.
He is a co-founder of cannabinoid prescription medicines investment group Diligenc Capital and the current chief medical officer of US-based biotechnology company Return Health, which is developing novel psychedelic treatments for patients with dementia.
Darryl Davies co-founded private medicinal cannabis service provider Cannvalate in 2018, where he led a patient access and distribution program and developed the Medicinal Cannabis Research Collaboration.
He is an Australian director of Canadian manufacturer The Valens Company and sits on the board of directors for New Zealand cultivation company Greenfern Industries.
Earlier this year, North American cannabis investment firm Ela Capital made its first foray into Australia, taking a nearly 9% stake in Lifespot.